AI in Psychiatry & Enterprise Profitability: Hope Therapeutics & Aeries Technology on NYSE

Hope Therapeutics: AI-Powered Depression Treatment

• 💡 Hope Therapeutics, owned by NRX Pharmaceuticals, has initiated patient care for treatment-resistant depression using the AMPA 1-day protocol.
• 🎯 This new protocol offers a faster treatment paradigm compared to the traditional 90-day TMS, with initial deployments in Sarasota, Naples, and Fort Myers, Florida.
• 🏥 Under the direction of Medical Director Dr. Rebecca Cohen, six Hope Clinic locations are planned in Florida by the end of the year.

Aeries Technology: Strong Financial Performance Driven by AI

• 📈 Aeries Technology announced strong financial results for its second quarter of fiscal year 2026, marking the strongest first half in the company's history.
• 💰 Revenue reached over $17 million, a 3% year-over-year increase, with net income swinging to positive from a prior-year loss.
• 🚀 Growth is attributed to consistent operational execution, expanded relationships within the private equity ecosystem, and the adoption of AI-enabled global delivery solutions.
• ✅ The company highlighted two quarters of profitability, positive operating cash flow, and the growing contribution of AI-enabled delivery and nearshore operations.